- Home
- SSTK vs LYEL Comparison
SSTK vs LYEL Comparison
Compare SSTK & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SSTK | LYEL |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 596.1M | 490.1M |
| IPO Year | 2012 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SSTK | LYEL |
|---|---|---|
| Price | $16.08 | $19.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $25.00 | ★ $27.25 |
| AVG Volume (30 Days) | ★ 271.5K | 80.6K |
| Earning Date | 05-01-2026 | 03-12-2026 |
| Dividend Yield | ★ 8.76% | N/A |
| EPS Growth | ★ 23.76 | N/A |
| EPS | ★ 1.25 | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | $4.35 | N/A |
| Revenue Next Year | N/A | $17,438.13 |
| P/E Ratio | $13.14 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.35 | $0.39 |
| 52 Week High | $29.50 | $45.00 |
Technical Indicators
Market Signals| Indicator | SSTK | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 41.19 | 38.14 |
| Support Level | $15.75 | $15.82 |
| Resistance Level | $17.81 | $27.30 |
| Average True Range (ATR) | 0.61 | 2.13 |
| MACD | 0.02 | -0.19 |
| Stochastic Oscillator | 14.97 | 20.96 |
Price Performance
Historical ComparisonAbout SSTK Shutterstock Inc.
Shutterstock Inc is a U.S.-based company that is engaged in the provision of digital content. The content segment, whose offerings include licenses for Images, Footage, Music, 3 Dimensional, and Generative AI content. Data, Distribution, and Service offerings address customer demand for products and services that are beyond its Content licenses. The company generates the majority of its revenue from Content offerings. Geographically the company generates the majority of its revenue from the Domestic market, but also has its presence in Europe and Rest of the Countries.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.